接受或不接受131I治疗的育龄甲状腺癌患者不孕风险:一项全国性基于人群的队列研究
该研究利用台湾全民健康保险数据库2009至2019年数据,纳入20,259例15至50岁甲状腺癌患者(8,037例未接受131I治疗,12,222例接受131I治疗)及20,259例对照,采用Cox比例风险模型估计不孕风险。结果显示,接受131I治疗、未接受131I治疗和对照组的不孕发生率分别为每1000人年5.55、5.07和3.61;与累计131I剂量≤4.44 GBq者相比,累计剂量>4.44 GBq者不孕风险未显著增加(校正HR 1.13,95%CI 0.95-1.36)。结论认为,育龄甲状腺癌患者不孕风险增加主要与患甲状腺癌本身相关,与是否接受131I治疗无关。
要点
- 接受131I治疗、未接受131I治疗和对照组的不孕发生率分别为每1000人年5.55、5.07和3.61。
- 与累计131I剂量≤4.44 GBq者相比,累计剂量>4.44 GBq者不孕风险未显著增加(校正HR 1.13,95%CI 0.95-1.36)。
- 结论认为育龄甲状腺癌患者不孕风险增加主要与患甲状腺癌本身相关,与131I治疗无关。
核心结论
- 育龄甲状腺癌患者不孕风险增加主要与患甲状腺癌本身相关,与是否接受131I治疗无关;131I治疗或累计剂量>4.44 GBq未进一步增加不孕风险。
研究设计与样本
- 全国性基于人群的队列研究,使用台湾全民健康保险数据库2009至2019年数据。
- 纳入20,259例15至50岁甲状腺癌患者(8,037例未接受131I治疗,12,222例接受131I治疗)及20,259例对照。
- 采用Cox比例风险模型估计不孕风险,以风险比和95%置信区间表示。
主要发现
- 接受131I治疗、未接受131I治疗和对照组的不孕发生率分别为每1000人年5.55、5.07和3.61。
- 与累计131I剂量≤4.44 GBq者相比,累计剂量>4.44 GBq者不孕风险未显著增加(校正HR 1.13,95%CI 0.95-1.36)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fertility is the crucial concern for many survivors of cancer diagnosed as children, adolescents, and young adults. The objective of this study was to determine the risk of infertility in reproductive-age patients with thyroid cancer receiving or not receiving radioiodine treatment in Taiwan. METHODS: This nationwide population-based cohort study was conducted using data obtained from the Taiwan National Health Insurance Database from 2009 to 2019. A total of 20,259 thyroid cancer patients aged from 15 to 50 years (8037 did not receive 131I treatment, and 12,222 received 131I treatment) and 20,259 controls were enrolled. A Cox proportional hazards model was applied to estimate the risk of infertility in thyroid cancer patients receiving or not receiving 131I treatment in terms of hazard ratios and 95% confidence intervals. RESULTS: The incidence rates of infertility in thyroid cancer receiving 131I therapy, those not receiving 131I therapy, and controls were 5.55, 5.07, and 3.61 per 1000 person-years, respectively. Compared with thyroid cancer patients treated with a cumulative 131I dose of 4.44 GBq or less, the risk of infertility was not significantly increased in those treated with a cumulative 131I dose of more than 4.44 GBq (adjusted hazard ratio, 1.13; 95% confidence interval, 0.95-1.36). CONCLUSIONS: The greatest increased risk of infertility in reproductive-age patients with thyroid cancer is associated with the fact that the patient has thyroid cancer regardless of 131I administration. 131I treatment or cumulative dose of 131I greater than 4.44 GBq did not further increase the risk of infertility.
引用
- Lin CY, Lin CL, Kao CH, et al. Risk of Infertility in Reproductive-Age Patients With Thyroid Cancer Receiving or Not Receiving 131I Treatment: A Nationwide Population-Based Cohort Study. Clin Nucl Med. 2024. PMID: 39894986. doi:10.1097/RLU.0000000000005570
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。